- Home
- TRUE vs LCTX Comparison
TRUE vs LCTX Comparison
Compare TRUE & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUE
- LCTX
- Stock Information
- Founded
- TRUE 2005
- LCTX 1990
- Country
- TRUE United States
- LCTX United States
- Employees
- TRUE N/A
- LCTX N/A
- Industry
- TRUE Computer Software: Programming Data Processing
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRUE Technology
- LCTX Health Care
- Exchange
- TRUE Nasdaq
- LCTX Nasdaq
- Market Cap
- TRUE 114.6M
- LCTX 107.3M
- IPO Year
- TRUE 2014
- LCTX N/A
- Fundamental
- Price
- TRUE $1.45
- LCTX $0.66
- Analyst Decision
- TRUE Buy
- LCTX Strong Buy
- Analyst Count
- TRUE 5
- LCTX 5
- Target Price
- TRUE $3.19
- LCTX $4.20
- AVG Volume (30 Days)
- TRUE 397.0K
- LCTX 1.1M
- Earning Date
- TRUE 05-05-2025
- LCTX 05-13-2025
- Dividend Yield
- TRUE N/A
- LCTX N/A
- EPS Growth
- TRUE N/A
- LCTX N/A
- EPS
- TRUE N/A
- LCTX N/A
- Revenue
- TRUE $179,356,000.00
- LCTX $9,557,000.00
- Revenue This Year
- TRUE $7.54
- LCTX N/A
- Revenue Next Year
- TRUE $11.02
- LCTX $232.66
- P/E Ratio
- TRUE N/A
- LCTX N/A
- Revenue Growth
- TRUE 10.18
- LCTX 19.42
- 52 Week Low
- TRUE $1.05
- LCTX $0.37
- 52 Week High
- TRUE $4.62
- LCTX $1.15
- Technical
- Relative Strength Index (RSI)
- TRUE 44.81
- LCTX 66.01
- Support Level
- TRUE $1.46
- LCTX $0.48
- Resistance Level
- TRUE $1.65
- LCTX $0.70
- Average True Range (ATR)
- TRUE 0.12
- LCTX 0.05
- MACD
- TRUE 0.00
- LCTX 0.02
- Stochastic Oscillator
- TRUE 14.71
- LCTX 69.26
About TRUE TrueCar Inc.
TrueCar Inc is a data-driven online platform operating on common technology infrastructure, powered by proprietary data and analytics. It also customizes and operates its platform for affinity group marketing partners, including financial institutions like PenFed and American Express; membership-based organizations like Consumer Reports, AARP, Sam's Club, and AAA; and employee buying programs for large enterprises such as IBM and Walmart. The Company has one operating segment, with three distinct service offerings: Dealer products and services, OEM incentives, and other.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.